BR112022001702A2 - Moléculas mhc classe ii e métodos de uso das mesmas - Google Patents
Moléculas mhc classe ii e métodos de uso das mesmasInfo
- Publication number
- BR112022001702A2 BR112022001702A2 BR112022001702A BR112022001702A BR112022001702A2 BR 112022001702 A2 BR112022001702 A2 BR 112022001702A2 BR 112022001702 A BR112022001702 A BR 112022001702A BR 112022001702 A BR112022001702 A BR 112022001702A BR 112022001702 A2 BR112022001702 A2 BR 112022001702A2
- Authority
- BR
- Brazil
- Prior art keywords
- class
- amino acid
- methods
- molecules
- hla
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880509P | 2019-07-30 | 2019-07-30 | |
| US202063029115P | 2020-05-22 | 2020-05-22 | |
| PCT/IB2020/057174 WO2021019474A1 (en) | 2019-07-30 | 2020-07-29 | Mhc class ii molecules and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022001702A2 true BR112022001702A2 (pt) | 2022-06-21 |
Family
ID=74230294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022001702A BR112022001702A2 (pt) | 2019-07-30 | 2020-07-29 | Moléculas mhc classe ii e métodos de uso das mesmas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220281949A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4004033A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7811541B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220052944A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114502580B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020319732B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022001702A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3146296A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290231A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022001211A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202118781A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021019474A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020231693A1 (en) | 2019-03-04 | 2021-09-30 | University Health Network | T cell receptors and methods of use thereof |
| TWI881991B (zh) * | 2019-07-30 | 2025-05-01 | 大學健康網絡 | Ii類mhc分子及其使用方法 |
| TW202116797A (zh) | 2019-07-30 | 2021-05-01 | 大學健康網絡 | Ii類mhc分子及其使用方法 |
| CN118662607B (zh) * | 2023-03-15 | 2026-07-07 | 中国科学院上海药物研究所 | 抑制过激炎性反应的蛋白及其应用 |
| US20250074966A1 (en) * | 2023-08-31 | 2025-03-06 | Adaptive Biotechnologies Corporation | Agents and methods for preventing or inhibiting adaptive immune responses associated with multiple sclerosis |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601801B2 (en) * | 2003-07-11 | 2009-10-13 | Dainippon Sumitomo Pharma Co., Ltd. | HLA-A24 binding cancer antigen peptide derived from livin |
| US20060228758A1 (en) * | 2004-09-13 | 2006-10-12 | Xencor, Inc. | Analysis of MHC-peptide binding interactions |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9738724B2 (en) * | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| US9717758B2 (en) * | 2013-05-17 | 2017-08-01 | University Of Massachusetts | High-affinity DMF5 T cell receptor (TCR) variants |
| WO2016135363A1 (es) * | 2015-02-23 | 2016-09-01 | Servicio Andaluz De Salud | Método de obtención de datos útiles para predecir o pronosticar la transmisión vertical, la cronificación y/o el aclaramiento del virus de la hepatitis c |
| MX2018006789A (es) * | 2015-12-03 | 2019-02-13 | Juno Therapeutics Inc | Receptores quimericos modificados y composiciones y metodos relacionados. |
| KR20180087430A (ko) * | 2015-12-17 | 2018-08-01 | 얀센 바이오테크 인코포레이티드 | Hla-dr에 특이적으로 결합하는 항체 및 이의 용도 |
| GB201604492D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| US12187781B2 (en) * | 2018-08-01 | 2025-01-07 | Regents Of The University Of Minnesota | Co-receptor affinity enhanced major histocompatibility class II molecules |
-
2020
- 2020-07-29 KR KR1020227006945A patent/KR20220052944A/ko active Pending
- 2020-07-29 TW TW109125667A patent/TW202118781A/zh unknown
- 2020-07-29 CA CA3146296A patent/CA3146296A1/en active Pending
- 2020-07-29 BR BR112022001702A patent/BR112022001702A2/pt unknown
- 2020-07-29 EP EP20847581.4A patent/EP4004033A4/en active Pending
- 2020-07-29 JP JP2022506468A patent/JP7811541B2/ja active Active
- 2020-07-29 MX MX2022001211A patent/MX2022001211A/es unknown
- 2020-07-29 AU AU2020319732A patent/AU2020319732B2/en active Active
- 2020-07-29 WO PCT/IB2020/057174 patent/WO2021019474A1/en not_active Ceased
- 2020-07-29 US US17/631,824 patent/US20220281949A1/en active Pending
- 2020-07-29 CN CN202080068318.7A patent/CN114502580B/zh active Active
-
2022
- 2022-01-30 IL IL290231A patent/IL290231A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020319732B2 (en) | 2026-07-09 |
| EP4004033A4 (en) | 2023-12-06 |
| US20220281949A1 (en) | 2022-09-08 |
| TW202118781A (zh) | 2021-05-16 |
| CA3146296A1 (en) | 2021-02-04 |
| JP2022542448A (ja) | 2022-10-03 |
| EP4004033A1 (en) | 2022-06-01 |
| WO2021019474A1 (en) | 2021-02-04 |
| CN114502580B (zh) | 2025-10-17 |
| IL290231A (en) | 2022-03-01 |
| KR20220052944A (ko) | 2022-04-28 |
| MX2022001211A (es) | 2022-05-03 |
| JP7811541B2 (ja) | 2026-02-05 |
| CN114502580A (zh) | 2022-05-13 |
| AU2020319732A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022001710A2 (pt) | Moléculas mhc de classe ii e métodos de uso das mesmas | |
| MX2022001211A (es) | Moléculas del complejo mayor de histocompatibilidad (mhc) de clase ii y métodos para su uso. | |
| BR112018000477A2 (pt) | proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural | |
| CY1122576T1 (el) | Ανθρωπινα αντισωματα που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (leg-3), και χρησεις εξ' αυτων | |
| AR060583A1 (es) | Anticuerpo de c- kit humanizado | |
| BR112012017124B8 (pt) | método para produzir e para purificar um multímero polipeptídico | |
| BR122021020829B8 (pt) | Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada | |
| BRPI0111191B8 (pt) | moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos | |
| BR112021018734A2 (pt) | Receptores de células t e métodos de uso destes | |
| BR112022001704A2 (pt) | Moléculas mhc de classe ii e métodos de uso das mesmas | |
| MX361299B (es) | Metodo para activar celulas auxiliares. | |
| AR080942A1 (es) | Produccion de proteinas heteromultimericas | |
| BRPI0612273C1 (pt) | anticorpo de ligação a il-1 beta ou fragmento de ligação a il-1 beta do mesmo, ácido nucleico, vetor, e, composição | |
| BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
| BR112021017464A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| BR112021012240A2 (pt) | Terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrich | |
| MX2022001204A (es) | Métodos de identificación de receptores de linfocitos t. | |
| BR112021017479A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| BR112021017491A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| BR112022015897A2 (pt) | Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v | |
| BR112021017505A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| BR112021017404A2 (pt) | Receptores de células t e métodos de uso dos mesmos | |
| BR112021026484A2 (pt) | Polimerização de enzimas para reações de sequenciamento | |
| MX2023002602A (es) | Composicion para inmunoterapia. | |
| BR112012024232A8 (pt) | "aptâmero de 73 nucleotídeos ou menos, complexo, composição farmacêutica e medicamento anti-dor" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |